share_log

Virpax Pharmaceuticals | 8-K: Current report

Virpax Pharmaceuticals | 8-K: Current report

Virpax製藥 | 8-K：重大事件
美股SEC公告 ·  10/03 16:36

Moomoo AI 已提取核心訊息

Virpax Pharmaceuticals, Inc., a Delaware-incorporated emerging growth company, has entered into a Material Definitive Extension Agreement with an institutional investor on September 30, 2024. This agreement is an amendment to the Securities Purchase Agreement (SPA) dated July 5, 2024, and pertains to a potential financing arrangement of not less than $5 million, referred to as the Subsequent Financing. The institutional investor retains exclusive negotiation rights and a right of first refusal for any Subsequent Financing until November 30, 2024, known as the Outside Date. If the financing is not secured by this date, the investor's nominated board members will resign immediately. The company has the option to extend the Outside Date by up to 30 days, with board approval, to accommodate the re-audit of financial statements for fiscal years 2022 and 2023. The full details of the Extension Agreement have been filed with the SEC and are incorporated into the Form 8-K report.
Virpax Pharmaceuticals, Inc., a Delaware-incorporated emerging growth company, has entered into a Material Definitive Extension Agreement with an institutional investor on September 30, 2024. This agreement is an amendment to the Securities Purchase Agreement (SPA) dated July 5, 2024, and pertains to a potential financing arrangement of not less than $5 million, referred to as the Subsequent Financing. The institutional investor retains exclusive negotiation rights and a right of first refusal for any Subsequent Financing until November 30, 2024, known as the Outside Date. If the financing is not secured by this date, the investor's nominated board members will resign immediately. The company has the option to extend the Outside Date by up to 30 days, with board approval, to accommodate the re-audit of financial statements for fiscal years 2022 and 2023. The full details of the Extension Agreement have been filed with the SEC and are incorporated into the Form 8-K report.
Virpax Pharmaceuticals, Inc.，一家於特拉華州註冊成立的新興成長公司，已於2024年9月30日與機構投資者簽署了一份具有重大確定性的展期協議。該協議是對於2024年7月5日簽署的證券購買協議（SPA）的修訂，涉及金額不低於$500萬的潛在融資安排，被稱爲後續融資。機構投資者保留獨家談判權以及截至2024年11月30日的第一購買權，即所謂的最晚日期。如果在此日期之前未獲得融資，投資者提名的董事會成員將立即辭職。公司有權在董事會批准的情況下將最晚日期延長最多30天，以便重新審計截至2022年和2023年財務報表。展期協議的完整細節已提交給美國證券交易委員會，並已納入第8-k表格報告中。
Virpax Pharmaceuticals, Inc.，一家於特拉華州註冊成立的新興成長公司，已於2024年9月30日與機構投資者簽署了一份具有重大確定性的展期協議。該協議是對於2024年7月5日簽署的證券購買協議（SPA）的修訂，涉及金額不低於$500萬的潛在融資安排，被稱爲後續融資。機構投資者保留獨家談判權以及截至2024年11月30日的第一購買權，即所謂的最晚日期。如果在此日期之前未獲得融資，投資者提名的董事會成員將立即辭職。公司有權在董事會批准的情況下將最晚日期延長最多30天，以便重新審計截至2022年和2023年財務報表。展期協議的完整細節已提交給美國證券交易委員會，並已納入第8-k表格報告中。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間